-- Total offering size of $345 million –
-- Incremental $200 million borrowing capacity secured under new
revolving credit facility --
DUBLIN--(BUSINESS WIRE)--Mar. 11, 2019--
Horizon Pharma plc (Nasdaq: HZNP) today announced the closing of its
underwritten public offering of 14,081,632 of its ordinary shares at a
price to the public of $24.50 per share. This includes the exercise in
full by the underwriters of their option to purchase up to 1,836,734
additional ordinary shares. The estimated net proceeds to the Company
from this offering are approximately $326.8 million, after deducting
underwriting discounts and other estimated offering expenses payable by
Citigroup, Morgan Stanley, Goldman Sachs & Co. LLC and Cowen acted as
joint book-running managers for the offering.
Also on March 11, 2019, the Company secured incremental revolving loan
commitments pursuant to an amendment to its existing credit agreement.
The new incremental revolving commitments have been established pursuant
to a revolving credit facility, and provide an additional $200 million
of borrowing capacity.
A registration statement relating to the ordinary shares described above
was previously filed with and became effective by rule of the Securities
and Exchange Commission (“SEC”). A final prospectus supplement and
accompanying prospectus related to the offering was filed with the SEC
and is available on the SEC’s website located at http://www.sec.gov.
Copies of the final prospectus supplement and accompanying prospectus
may be obtained by contacting Citigroup Global Markets Inc., c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY
11717 or by phone at 800-831-9146; Morgan Stanley & Co. LLC, 180 Varick
Street, 2nd Floor, New York, NY 10014, Attention:
Prospectus Department; Goldman Sachs & Co. LLC, c/o: Prospectus
Department, 200 West Street, New York, NY 10282, by email at firstname.lastname@example.org
or by phone at 866-471-2526; or Cowen and Company, LLC, c/o Broadridge
Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn:
Prospectus Department or by phone at 631-274-2806.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, the
shares in any state or other jurisdiction which such offer, solicitation
or sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other jurisdiction.
About Horizon Pharma plc
Horizon Pharma plc is focused on researching, developing and
commercializing innovative medicines that address unmet treatment needs
for rare and rheumatic diseases. By fostering a growing pipeline of
medicines in development and exploring all potential uses for currently
marketed medicines, we strive to make a powerful difference for
patients, their caregivers and physicians. For us, it’s personal: by
living up to our own potential, we are helping others live up to theirs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190311005809/en/
Source: Horizon Pharma plc
Senior Vice President, Investor Relations
Executive Director, Investor Relations
U.S. Media Contact:
President, Corporate Affairs & Chief Communications Officer
Ireland Media Contact: